Related News
Home 禄 Business 禄 Manufacturing
Boehringer sets up animal vaccine joint venture
By Ding Yining |
May 31, 2012, Thursday
|
Online Edition
Online Edition
GERMAN drug maker Boehringer Ingelheim said it has set up a 55.5 million euro (US$68.7 million) joint venture to produce animal vaccines in Taizhou, Jiangsu Province.
The joint venture with China Medical City - both parties have a 50 percent stake - is expected to boost the pharmaceutical company's production capacity to serve the growing domestic animal health market.
The manufacturing site is expected to open near the end of 2014. It is another step for Boehringer to boost its animal vaccines business following the announcement of the establishment of a research and development facility in Shanghai's Zhangjiang High-tech Park in March.
The 12 million-euro Asian Veterinary Research & Development Center unveiled in March is the first animal health R&D facility set up by a multinational drug maker in China. It's Boehringer's third outside Germany and the United States.
The localization of the research, production and sales sectors of Boehringer's animal health business shows the firm's long-term commitment to the Chinese market.
The production site will make vaccines targeted at specific diseases among pigs and poultry and will allow the firm to address local demands more quickly and flexibly.
The joint venture with China Medical City - both parties have a 50 percent stake - is expected to boost the pharmaceutical company's production capacity to serve the growing domestic animal health market.
The manufacturing site is expected to open near the end of 2014. It is another step for Boehringer to boost its animal vaccines business following the announcement of the establishment of a research and development facility in Shanghai's Zhangjiang High-tech Park in March.
The 12 million-euro Asian Veterinary Research & Development Center unveiled in March is the first animal health R&D facility set up by a multinational drug maker in China. It's Boehringer's third outside Germany and the United States.
The localization of the research, production and sales sectors of Boehringer's animal health business shows the firm's long-term commitment to the Chinese market.
The production site will make vaccines targeted at specific diseases among pigs and poultry and will allow the firm to address local demands more quickly and flexibly.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
